TP508: a new drug for mitigating lethal effects of radiatin exposure
Ended Project Grant Awarded Last action
- Award ID
- R44AI086135
- Recipient
-
Chrysalis Biotherapeutics, Inc. UEI XW1VFGGRLDW3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,789,079
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Galveston, TX 77550, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $978,663 | |
| Amendment | $810,416 | |
| Original award | $1,000,000 |
Quick answers
Who received award R44AI086135?
R44AI086135 was awarded to Chrysalis Biotherapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 15, 2010.
How much is award R44AI086135 worth?
$5,789,079 has been obligated on R44AI086135.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award